Document ID: chunk:federal_register_of_legislation:F2025C00201:reg:13761
Version: federal_register_of_legislation:F2025C00201
Segment Type: reg
Provision Reference: reg 13761
Character Range: 7794–9539

13761                                            Extracorporeal photopheresis for the treatment of chronic graft‑versus‑host disease, if:                                                                                                 1,908.35
                                                   (a) the person is:
                                                       (i) has received allogeneic haematopoietic stem cell transplantation; and
                                                       (ii) has been diagnosed with chronic‑graft‑versus host disease following the transplantation; and
                                                       (iii) steroid treatment is clinically unsuitable as the disease is steroid refractory or the person is steroid‑dependent or steroid‑intolerant; and
                                                   (b) the person has not previously received extracorporeal photopheresis treatment; and
                                                   (c) the service is delivered using an integrated, closed extracorporeal photopheresis system; and
                                                   (d) the service is provided in combination with the use of methoxsalen that is listed on the Pharmaceutical Benefits Scheme; and
                                                   (e) the service is provided by, or on behalf of, a specialist or consultant physician who:
                                                       (i) is practising in the speciality of haematology or oncology; and
                                                       (ii) has experience with allogeneic bone marrow transplantation.

                                                 Applicable once per treatment session (H)